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with inﬂammatory bowel disease are at an even greater risk of acute
and chronic radiation-induced injury, with one study ﬁnding an overall
incidence of severe enteric toxicity at 46% (Willett et al., 2000). Here we
describe the case of a patientwith cervical cancer and severe inﬂamma-
tory bowel disease, in whom a saline-ﬁlled tissue expander was placed
prior to radiotherapy with the goal of removing the small bowel from
the radiation ﬁeld.
2. Case
A 40-year old woman presented to her family doctor with a one
month history of abnormal vaginal bleeding and pelvic pain. Her medi-mental resections. Fourteen years prior to consultation, she had a bowel1. Introduction
Radiation therapy plays a critical role in the treatment of cervical
cancer, and chemoradiation is the treatment of choice in patients with
advanced cervical cancer. However, the dose of radiation that can be
delivered to the pelvis is limited by the variations in normal tissue
tolerance of other intra-pelvic structures (small and large bowels,
rectums, and bladders) to radiation. Target radiation treatment doses
exceed the maximal value of small bowel radiation tolerance, leading
to acute toxicity (diarrhea, abdominal cramps, and nausea (Geller
et al., 2009)). Late complications of radical radiotherapy for cervical can-
cer arise in 5–15% of patients (Hamberger et al., 1983); the toxic effects
of radiation on the bowel can lead to ﬁbrosis, constriction, and stenosis
(Geller et al., 2009). These risks increasewith patient history of prior ab-
dominal surgery, smoking, pelvic inﬂammatory disease, and diabetes
(Berek and Hacker, 2009). In the absence of these risk factors, the
small bowel can tolerate radiation doses to 30 Gy; the risk of small
bowel obstruction rises rapidly at doses greater than 60 Gy, and reachesfor Women, Robbins Pavilion,
nton, Alberta T5H 3V9, Canada.
. This is an open access article undercal historywas signiﬁcant for a 24-year history of Crohn's diseasewhich
had been managed surgically as she could not tolerate her medications
for various reasons. Over a period of 12 years she had undergone 11 seg-
resection with incidental right salpingo-oophorectomy and subtotal
hysterectomy, ostensibly because of adhesions between the bowel and
uterus and adnexa. At the time the patient presented to her family doc-
tor, she had not had a Pap smear for fourteen years, as she was not
aware that she still had a cervix.
A Pap smear was performed and cytology showed a high-grade
squamous intraepithelial lesion (HSIL). On colposcopy, an endocervical
curettage also showed HSIL, and a biopsy taken in a loop electrosurgical
excision procedure showed extensive poorly-differentiated squamous
cell carcinoma. A bimanual exam revealed a 5–6 cm mass palpable in
the upper vagina.
OnMRI, a 5-cmmass was seen inﬁltrating the remnant of the cervix,
with extension into the parametria and proximal half of the vagina
(FIGO Stage IIB). Enlarged, irregular pelvic lymph nodes were seen, al-
though it was unclear whether these were related to her malignancy
or Crohn's disease. A PET scan showed intense radiotracer in the cervical
malignancy with multiple metabolically active parailiac lymph nodes
bilaterally, consistent with nodal metastases. Both small and large
bowels were FDG-avid.
The size of the malignancy and the suspicious pelvic lymph nodes
made this patient a candidate for radical radiotherapy with cisplatin
chemotherapy; however, there was concern that her Crohn's disease
would be aggravated with radiation.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Examples in the Literature of Pelvic Prosthesis Insertion in Order to Prevent Radiation Enterotoxicity.
Author and year Number
of patients
Indication Tissue expander
(TE) ﬁlled to: (cm3)
Mesh Radiation enteritis Complications due to prosthesis
Sugarbaker 1983 1 Unspeciﬁed 1000 Prosthetic mesh none none
Lasser 1986 9 Rectal cancer ? ? none none
Cuttat 1991 4 Rectal cancer 500 ? none none
Herbert 1993 14 Endometrial, colorectal, anal cancer 450–850 none Statistical decrease in enteritis in patients with
TE placement (compared to 63 patients not
receiving TE)
Ileus (n = 1)
Bowel perforation after removal of TE (n = 2)
Perineal dehiscence in patient with transvaginal placement of
TE in pelvic exenteration (n = 1)
Delaloye 1994 18 Cervical cancer 350–400 Vicryl mesh none Hydronephrosis (n = 1)
Constipation (n = 1)
Hoffman 1998 58 Sarcomas; endometrial, vaginal, cervical, rectal,
colon, anal cancer
450–1500 none none Abscess (n = 4), ﬁstula (n = 4),TE extrusion (n = 1), TE
deﬂation (n = 3)
Sezeur 1999 22 Retroperitoneal sarcoma, pelvic cancer 600 Vicryl mesh none Heaviness (n = 1)
Flank pain (n = 2)
Bowel injury during positioning of tissue expander (n = 1)
Burnett 2000 7 Cervical cancer 960–1200 none none Adhesions of bowel to implant (n = 1)
PE (n = 1)
Abhyankar 2005 1 Retroperitoneal rhabdomyosarcoma 250 Vicryl mesh none none
Holmebakk 2006 1 Retroperitoneal recurrence of colorectal cancer 500 none none none
White 2007 33 Sarcomas, endometrial, vaginal, colon, rectal
cancer
700 Dexon mesh none Cystitis (n = 1)
Ileus (n = 1)
Angster 2010 2 Cervical cancer, retroperitoneal sarcoma 400 none none none
500
Geller 2009 10 Cervical cancer 720 none none Migration implant (n = 1)
Vesicovaginal ﬁstula (n = 1)
Enterocutaneous ﬁstula (n = 1)
Rectovaginal ﬁstula (n = 1)
McKay 2011 1 Prostate cancer 350 none none none
Valle 2011 28 Cervical cancer ? none none Fever (n = 4), periprosthetic hemorrhage effusion (n = 2)
Perez-Munoz, 2014 20 Pelvic Ewing's sarcoma ~500 none none Mild diarrhea (n = 1)
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weekly for six weeks) was offered, with the intention of shrinking the
tumor. If adequate shrinkage of the tumor resulted, laparotomy with
pelvic node dissection and radical trachelectomy could be performed.
A tissue expander would be placed in the pelvis in order to move the
bowel out of the radiation ﬁeld. After surgery, we planned to administer
external beam radiotherapy.
AnMRI performed on completion of the neoadjuvant chemotherapy
showed signiﬁcant shrinkage of the lesion, but it appeared to be very
close (if not inﬁltrating) to the rectum. Trachelectomy with colostomy
was proposed, but the patient refused to consent to colostomy. There-
fore only laparotomy with pelvic lymphadenectomy was performed.
At this time, a tissue expander (ﬁlled with 600 cm3 of normal saline)
was inserted into the pelvis, and a Vicryl mesh hammock was placed
to prevent the small bowel from sliding down around the expander. Pa-
thology resulted showing two of nine pelvic lymph nodes being positive
for metastatic squamous cell carcinoma.
External beam radiotherapy using an intensitymodulated technique
was started 17 days after pelvic lymph node dissection and placement
of the tissue expander. A dose of 45 Gy was delivered in 25 fractions
over ﬁve weeks to a volume containing the primary cancer, upper
vagina, paracervical tissues and lymph node areas at risk. Cis-platin
30 mg/m2 was given weekly during this treatment. A boost dose of
20 Gy in ten fractions over twoweekswas then delivered to the cervical
stump. Interstitial brachytherapy was not used as it would not have
been possible to encompass the entire cervical stump in the high dose
volume that can be achieved with interstitial needles without punctur-
ing the prosthesis.
During theﬁveweeks of radiotherapy, thepatient developed bilater-
al deep vein thromboses, a small pulmonary embolism, and a right renal
vein thrombosis, requiring the placement of an inferior vena cava ﬁlter.
She had severe pain and edema in both legs; it was unclearwhether this
was secondary to her thromboses or the tissue expander. At the comple-
tion of radiotherapy, she underwent laparotomy to remove the tissue
expander, and on examination under anesthesia prior to laparotomy, a
very small, low rectovaginal ﬁstula was seen. It was distal to the lower
edge of the radiation ﬁeld and thought to be a pre-existing, previously
undiagnosed consequence of her Crohn's disease. It may explain the
patient's history of occasional incontinence when her stools were
loose. The ﬁstula spontaneously resolved shortly after. The patient has
not developed any symptoms of radiation enteritis to date, and approx-
imately eight months after removal of the tissue expander, she is well
with no recurrence of her cervical malignancy.
3. Comment
In 1983, Sugarbaker was the ﬁrst to describe insertion of a silicone
breast implant into the pelvis, with a small bowel suspended above
the radiation ﬁeld by a prosthetic mesh sling (Sugarbaker, 1983). To
our knowledge, there have beenmore than 200 cases since 1983 describ-
ing insertion of tissue expanders (TEs) into the pelvis to protect the small
bowel from radiation (Table 1). These cases include gynecologic malig-
nancies, colorectal and prostate cancers, and abdominal sarcomas.
The beneﬁt of TEs include easy insertion and removal, lack of adher-
ence to bowel or peritoneum, resistance to degradation by radiation,
and being similar in density to human tissue, thereby not altering iso-
dose distribution of radiation (McKay et al., 2011). However, radiation
cystitis and proctitis remain common, as the TE does not protect the uri-
nary bladder, ureters, or rectum. In addition, the TE exerts a mass effect
on surrounding structures (colon, ureters, urinary bladder, iliac vessels),
whichmay lead to thromboembolism (Burnett et al., 2000), a sensation
of heaviness (Sezeur et al., 1999), hydronephrosis and constipation
(Delaloye et al., 1994). These risks increase with the size of the TE
(McKay et al., 2011).
It is difﬁcult to deduce what role the TE may have played in our pa-
tient developing multiple thromboembolisms, since malignancy,Crohn's disease, chemotherapy, and radiotherapy all increase the risk
of thromboembolic events. On reviewing the literature, TE volumes
between 250 and 1500 cm3 have been reported; only one study (7)
reported a thromboembolic event, while using volumes between 960
and 1200 cm3 (Table 1).While the tissue expanderwe usedwas no larg-
er than many ovarian masses, and by no means tightly wedged in the
pelvis, we would consider using a smaller TE volume in the future.
In the largest published study (Hoffman et al., 1998) of TE placement
to date, Hoffman et al. describe enterocutaneous ﬁstula development in
four of 58 patients; three patients developed ﬁstulae after TE removal,
and one prior to removal. Two of these ﬁstulae (one pre-TE removal,
one post-) were associated with abscesses that had formed around the
TE. Geller et al. (Geller et al., 2009) describes three of ten patients devel-
oping ﬁstulae: the ﬁrst, a vesicovaginal ﬁstula that formed while the TE
was in situ, the second a rectovaginal ﬁstula eighteen months after re-
moval of the TE, and the third an enterocutaneous ﬁstula associated
with an abscess while the TE was in situ. Our patient was found to
have a tiny rectovaginal ﬁstula prior to the period of radiotherapy; how-
ever, this formed outside of the radiation ﬁeld, and healed spontaneous-
ly shortly thereafter. As per Hoffman's study, the incidence of infection,
abscess formation, and ﬁstulization with tissue expander placement are
7% (Hoffmanet al., 1998). However,we believe thisﬁstula pre-dated the
placement of the tissue expander, and was secondary to her Crohn's
disease.
We elected to place both a tissue expander with a Vicryl mesh ham-
mock because of reports of TE migration and loops of the small bowel
slipping down into the radiation ﬁeld (Geller et al., 2009). Several
studies (Sezeur et al., 1999; Delaloye et al., 1994) have described the
concomitant use of a Vicryl mesh hammock with a TE. Of eighteen pa-
tients described by Delaloye et al. (Delaloye et al., 1994), one experi-
enced constipation and the other transient bilateral hydronephrosis.
Of twenty-two patients described by Sezeur et al. (Sezeur et al., 1999),
two experienced ﬂank pain (necessitating deﬂation of the TE between
radiation sessions), and one required the TE to be removed because of
an infection secondary to an injury to the bowel caused during TE posi-
tioning. Some authors (Dasmahapatra and Swaminathan, 1991; Rodier
et al., 1991) have described the use of a Vicryl mesh alone, however
the drawback to this method is that mesh degrades approximately
one month after placement, necessitating early radiotherapy. This is
not always possible, especially in patients with a complicated postoper-
ative course (Sezeur et al., 1999).
To our knowledge, this is the ﬁrst description of a case inwhich a tis-
sue expanderwas placed to reduce the risk of radiation enteritis in a pa-
tient with inﬂammatory bowel disease. The overall complication rate
associated with TE placement has been estimated to range between 5
and 40% (Geller et al., 2009) based on major prospective trials. Given
the risks of TE, this therapeutic strategy can be considered for patients
at a high risk for radiation toxicity as illustrated in this patient with
multiple prior surgeries and inﬂammatory bowel disease.4. Consent
Written informed consent was obtained from the patient for
publication of this case report and accompanying images. A copy of
the written consent is available for review by the Editor-in-Chief of
this journal on request.Conﬂict of interest statement
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